Education
About Us
Working with TipRanks
Follow Us
Kidswell Bio Corporation (JP:4584)
:4584
4584 Stock Chart & Stats
¥203.00
¥2.00(1.89%)
At close: 4:00 PM EST
¥203.00
¥2.00(1.89%)
Day’s Range― - ―
52-Week Range¥93.00 - ¥417.00
Previous CloseN/A
Volume149.00K
Average Volume (3M)766.13K
Market Cap
¥13.15B
Enterprise Value¥11.98B
Total Cash (Recent Filing)¥2.84B
Total Debt (Recent Filing)¥1.55B
Price to Earnings (P/E)―
Beta1.24
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.20
Shares Outstanding49,611,320
10 Day Avg. Volume871,200
30 Day Avg. Volume766,126
Financial Highlights & Ratios
PEG Ratio2.17
Price to Book (P/B)3.22
Price to Sales (P/S)0.89
P/FCF Ratio4.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained, large revenue growth signals expanding commercial traction and product/service adoption. Over a 2–6 month horizon this supports scaling benefits, improves leverage for fixed costs, and provides a larger base to convert future operational improvements into sustainable profitability and reinvestment.
Operating And Free Cash Flow Turned PositivePositive operating and free cash flow represent a durable improvement in cash-generation ability, reducing reliance on external financing. This strengthens runway for clinical and manufacturing investments, lowers near-term funding risk, and increases flexibility to prioritize profitable growth initiatives.
Improved Liquidity And Reasonable Equity FundingA clearer cash buffer and a reasonable equity funding mix support resilience through multi-quarter development cycles. Improved liquidity lowers short-term refinancing risk, enabling continued R&D and scale-up execution while providing optionality for partnerships or targeted capital spending.
Bears Say
Persistent Net LossesOngoing net losses are a structural constraint: they erode shareholder equity and mean the business remains dependent on external capital. Over months this raises dilution and refinancing risk, complicates long-term planning, and delays the point at which organic earnings can fund growth and R&D.
High Debt-to-equity / Leverage RiskMaterial leverage increases financial fixed costs and reduces strategic flexibility. In a development-heavy biotech, high debt magnifies downside from clinical or regulatory delays, can force costly refinancing or covenant pressure, and constrains the company’s ability to invest opportunistically.
Negative Margins And Operational InefficienciesLow and negative margins indicate the company still struggles to convert revenue into sustainable profits. Without durable margin expansion, revenue growth may not translate into self-funded development or commercialization, keeping dependence on external capital and pressuring long-term return metrics.
Kidswell Bio Corporation News
4584 FAQ
What was Kidswell Bio Corporation’s price range in the past 12 months?
Kidswell Bio Corporation lowest stock price was ¥93.00 and its highest was ¥417.00 in the past 12 months.
What is Kidswell Bio Corporation’s market cap?
Kidswell Bio Corporation’s market cap is ¥13.15B.
When is Kidswell Bio Corporation’s upcoming earnings report date?
Kidswell Bio Corporation’s upcoming earnings report date is May 07, 2026 which is in 62 days.
How were Kidswell Bio Corporation’s earnings last quarter?
Kidswell Bio Corporation released its earnings results on Feb 12, 2026. The company reported -¥4.2 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.2.
Is Kidswell Bio Corporation overvalued?
According to Wall Street analysts Kidswell Bio Corporation’s price is currently Overvalued.
Does Kidswell Bio Corporation pay dividends?
Kidswell Bio Corporation does not currently pay dividends.
What is Kidswell Bio Corporation’s EPS estimate?
Kidswell Bio Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kidswell Bio Corporation have?
Kidswell Bio Corporation has 49,611,320 shares outstanding.
What happened to Kidswell Bio Corporation’s price movement after its last earnings report?
Kidswell Bio Corporation reported an EPS of -¥4.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.769%.
Which hedge fund is a major shareholder of Kidswell Bio Corporation?
Currently, no hedge funds are holding shares in JP:4584
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kidswell Bio Corporation
Kidswell Bio Corporation develops pharmaceuticals for the treatment of rare and intractable diseases in Japan. Its pipeline products include GND-004 for the treatment of ophthalmic disease and oncology; GND-007 for the treatment of immunological disease; and antibodies for oncology. The company pipeline products also include GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for ophthalmic disease; GBS-008 for infectious diseases; and GBS-011 for renal disease. In addition, its products also include GCT-101 for alveolar cleft; GCT-102 for congenital isolated hypoganglionosis; and other pipeline products for ophthalmologic diseases, cerebral palsy, peripheral nerve palsy, fracture, and spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―